Merck & Co., Inc. Foreign Currency Transaction Gain (Loss), Realized
Merck & Co., Inc. (MRK) reported Foreign Currency Transaction Gain (Loss), Realized of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossRealized · last filed 2018-02-27
- Merck & Co., Inc. foreign currency transaction gain (loss), realized for the quarter ending 2016-12-31 was $0.00.
- Merck & Co., Inc. foreign currency transaction gain (loss), realized for the quarter ending 2016-09-30 was $0.00.
- Merck & Co., Inc. foreign currency transaction gain (loss), realized for the quarter ending 2015-12-31 was -$161.00M.
- Merck & Co., Inc. foreign currency transaction gain (loss), realized for the quarter ending 2015-09-30 was $0.00.
- Merck & Co., Inc. foreign currency transaction gain (loss), realized for fiscal 2017 was $0.00.
- Merck & Co., Inc. foreign currency transaction gain (loss), realized for fiscal 2016 was $0.00.
- Merck & Co., Inc. foreign currency transaction gain (loss), realized for fiscal 2015 was -$876.00M.
- Merck & Co., Inc. foreign currency transaction gain (loss), realized for fiscal 2014 was $0.00.
| Period end | Foreign Currency Transaction Gain (Loss), Realized 3 month | Foreign Currency Transaction Gain (Loss), Realized 6 month | Foreign Currency Transaction Gain (Loss), Realized 9 month | Foreign Currency Transaction Gain (Loss), Realized 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-02-27 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $0.00 derived: sum of 2 quarters · filed 2018-02-27 | $0.00 10-K · filed 2018-02-27 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $0.00 10-Q · filed 2016-11-07 | ||
| 2016-06-30 | $0.00 10-Q · filed 2016-08-08 | |||
| 2015-12-31 | -$161.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$161.00M derived: sum of 2 quarters · filed 2018-02-27 | -$876.00M 10-K · filed 2018-02-27 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | -$715.00M 10-Q · filed 2016-11-07 | ||
| 2015-06-30 | -$715.00M 10-Q · filed 2016-08-08 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $0.00 derived: sum of 2 quarters · filed 2017-02-28 | $0.00 10-K · filed 2017-02-28 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $0.00 10-Q · filed 2015-11-05 | ||
| 2014-06-30 | $0.00 10-Q · filed 2015-08-06 | |||
| 2013-12-31 | -$140.00M 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |